# iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

> **NCT04808791** · PHASE2 · COMPLETED · sponsor: **AHS Cancer Control Alberta** · enrollment: 7 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Advanced Gastric Carcinoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** TAS 102 (Trifluridine/Tipiracil)

## Key facts

- **NCT ID:** NCT04808791
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-21
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808791, "iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04808791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*